Advertisement

Tumor Biology

, Volume 37, Issue 7, pp 9745–9753 | Cite as

Carboxypeptidase E is a prediction marker for tumor recurrence in early-stage hepatocellular carcinoma

  • Shiu-Feng Huang
  • Hong-Dar Isaac Wu
  • Ya-Ting Chen
  • Saravana R. K. Murthy
  • Yu-Ting Chiu
  • Yu Chang
  • Il-Chi Chang
  • Xuyu Yang
  • Y. Peng Loh
Original Article

Abstract

Tumor recurrence and metastasis are the major causes of death for hepatocellular carcinoma (HCC) patients who are able to receive curative resection. Identifying the predicting biomarkers for tumor recurrence would improve their survival. RNA extracted from fresh frozen tumors and adjacent non-tumor liver tissues of 120 HCC patients were obtained from Taiwan Liver Cancer Network (TLCN) in year 2010 for determination of the carboxypeptidase E (CPE) expression level (including its splicing mutant CPE-ΔN) in the tumor tissue (T) and paired non-tumor liver tissue (N) by real-time quantitative polymerase chain reaction. All patients were male, had chronic hepatitis B virus infection, were in the early pathology stage, and received curative resection. The T/N ratio of the CPE expression level was correlated with the updated survival data from TLCN in 2015. The CPE expression level in the 120 HCC patients was divided into three groups according to the T/N ratio: <1, ≥1 and ≤2, and >2, respectively. By multivariate analyses, the recurrence-free survival (RFS) was only significantly associated with the pathology stage and the CPE expression level. For overall survival (OS), only the CPE expression level was the significant prognostic factor. The CPE expression level was also significantly correlated with the tumor recurrence for both stage I (p = 0.0106) and stage II patients (p = 0.0006). The CPE mRNA expression level in HCC can be a useful biomarker for predicting tumor recurrence in HCC patients who are in the early pathology stage and able to receive curative resection.

Keywords

Carboxypeptidase E Hepatocellular carcinoma Recurrence-free survival Overall survival Biomarker 

Abbreviations

CPE

Carboxypeptidase E

HCC

Hepatocellular carcinoma

TLCN

Taiwan Liver Cancer Network

T

Tumor tissue

N

Paired non-tumor liver tissue

RFS

Recurrence-free survival

OS

Overall survival

AFP

Alpha-fetal protein

Notes

Acknowledgments

We would like to thank Taiwan Liver Cancer Network (TLCN) for providing the liver tissue samples and related clinical data (all are anonymous) for our research. The tissue source is the five major medical centers in Taiwan: National Taiwan University Hospital, Chang Gung Memorial Hospital Linko, Taichung Veteran General Hospital, Chang Gung Memorial Hospital Kaohsiung, and Kaohsiung Veteran General Hospital. TLCN is supported by grants from the Ministry of Science and Technology (MOST 103-2325-B-182-011, MOST 104-2325-B-182-002) and National Health Research Institutes, Taiwan.

Compliance with ethical standards

The study protocol has been approved by the Institutional Review Board of National Health Research Institutes, Taiwan (NIRB EC0990701).

Financial support

This research was supported by grants from National Science Council (NSC-100-c-2320-400-012) and National Health Research Institutes (MG103-PP-004) to Dr. Shiu-Feng Huang and by the Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, USA (HD008804) to Dr. Y. Peng Loh.

Conflicts of interest

None

References

  1. 1.
    El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and carcinogenesis. Gastroenterology. 2007;132:2557–76.CrossRefPubMedGoogle Scholar
  2. 2.
    Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245–55.CrossRefPubMedGoogle Scholar
  3. 3.
    Dhanasekaran R, Limaye A, Cabrera R. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics. Hepat Med. 2012;4:19–37.PubMedPubMedCentralGoogle Scholar
  4. 4.
    Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 2005;25:181–200.CrossRefPubMedGoogle Scholar
  5. 5.
    Jarnagin WR. Management of small hepatocellular carcinoma: a review of transplantation, resection, and ablation. Ann Surg Oncol. 2010;17:1226–33.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Lu LC, Cheng AL, Poon RT. Recent advances in the prevention of hepatocellular carcinoma recurrence. Semin Liver Dis. 2014;34:427–34.CrossRefPubMedGoogle Scholar
  7. 7.
    Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, Wong J. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer. 2000;89:500–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Dahiya D, Wu TJ, Lee CF, Chan KM, Lee WC, Chen MF. Minor versus major hepatic resection for small hepatocellular carcinoma (HCC) in cirrhotic patients: a 20-year experience. Surgery. 2010;147:676–85.CrossRefPubMedGoogle Scholar
  9. 9.
    Lai MW, Huang SF, Lin SM, Chen TC, Lin CY, Yeh CN, et al. Expression of the HCRP1 mRNA in HCC as an independent predictor of disease-free survival after surgical resection. Hepatol Res. 2009;39:164–76.CrossRefPubMedGoogle Scholar
  10. 10.
    Tanaka S, Mogushi K, Yasen M, Ban D, Noguchi N, Irie T, et al. Oxidative stress pathways in noncancerous human liver tissue to predict hepatocellular carcinoma recurrence: a prospective, multicenter study. Hepatology. 2011;54:1273–81.CrossRefPubMedGoogle Scholar
  11. 11.
    Zhu HT, Dong QZ, Sheng YY, Wei JW, Wang G, Zhou HJ, et al. MicroRNA-29a-5p is a novel predictor for early recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection. PLoS One. 2012;7, e52393.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Wu J, Du J, Liu L, Li Q, Rong W, Wang L, et al. Elevated pretherapy serum IL17 in primary hepatocellular carcinoma patients correlate to increased risk of early recurrence after curative hepatectomy. PLoS One. 2012;7, e50035.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Yu MC, Lee YS, Lin SE, Wu HY, Chen TC, Lee WC, et al. Recurrence and poor prognosis following resection of small hepatitis B-related hepatocellular carcinoma lesions are associated with aberrant tumor expression profiles of glypican 3 and osteopontin. Ann Surg Oncol. 2012;19(3):S455–63.CrossRefPubMedGoogle Scholar
  14. 14.
    Lee TK, Murthy SR, Cawley NX, Dhanvantari S, Hewitt SM, Lou H, et al. An N-terminal truncated carboxypeptidase E splice isoform induces tumor growth and is a biomarker for predicting future metastasis in human cancers. J Clin Invest. 2011;121:880–92.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Fricker LD, Carboxypeptidase E. Annu Rev Physiol. 1988;50:309–21.CrossRefPubMedGoogle Scholar
  16. 16.
    Manser E, Fernandez D, Loo L, Goh PY, Monfries C, Hall C, et al. Human carboxypeptidase E. Isolation and characterization of the cDNA, sequence conservation, expression and processing in vitro. Biochem J. 1990;267:517–25.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Cawley NX, Wetsel WC, Murthy SR, Park JJ, Pacak K, Loh YP. New roles of carboxypeptidase E in endocrine and neural function and cancer. Endocr Rev. 2012;33:216–53.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Cool DR, Normant E, Shen F, Chen HC, Pannell L, Zhang Y, et al. Carboxypeptidase E is a regulated secretory pathway sorting receptor: genetic obliteration leads to endocrine disorders in Cpe(fat) mice. Cell. 1997;88:73–83.CrossRefPubMedGoogle Scholar
  19. 19.
    Dhanvantari S, Loh YP. Lipid raft association of carboxypeptidase E is necessary for its function as a regulated secretory pathway sorting receptor. J Biol Chem. 2000;275:29887–93.CrossRefPubMedGoogle Scholar
  20. 20.
    Cheng Y, Cawley NX, Loh YP. Carboxypeptidase E/NFα1: a new neurotrophic factor against oxidative stress-induced apoptotic cell death mediated by ERK and PI3-K/AKT pathways. PLoS One. 2013;8, e71578.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Cheng Y, Rodriguiz RM, Murthy SR, Senatorov V, Thouennon E, Cawley NX, et al. Neurotrophic factor-α1 prevents stress-induced depression through enhancement of neurogenesis and is activated by rosiglitazone. Mol Psychiatry. 2015;20:744–54.CrossRefPubMedGoogle Scholar
  22. 22.
    Murthy SR, Dupart E, Al-Sweel N, Chen A, Cawley NX, Loh YP. Carboxypeptidase E promotes cancer cell survival, but inhibits migration and invasion. Cancer Lett. 2013;341:204–13.CrossRefPubMedGoogle Scholar
  23. 23.
    Murthy SR, Pacak K, Loh YP. Carboxypeptidase E: elevated expression correlated with tumor growth and metastasis in pheochromocytomas and other cancers. Cell Mol Neurobiol. 2010;30:1377–81.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Wang XC, Xu SY, Wu XY, Song HD, Mao YF, Fan HY, et al. Gene expression profiling in human insulinoma tissue: genes involved in the insulin secretion pathway and cloning of novel full-length cDNAs. Endocr Relat Cancer. 2004;11:295–303.CrossRefPubMedGoogle Scholar
  25. 25.
    He P, Varticovski L, Bowman ED, Fukuoka J, Welsh JA, Miura K, et al. Identification of carboxypeptidase E and gamma-glutamyl hydrolase as biomarkers for pulmonary neuroendocrine tumors by cDNA microarray. Hum Pathol. 2004;35:1196–209.CrossRefPubMedGoogle Scholar
  26. 26.
    Zhou K, Liang H, Liu Y, Yang C, Liu P, Jiang X. Overexpression of CPE-DeltaN predicts poor prognosis in colorectal cancer patients. Tumour Biol. 2013;34:3691–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Liang XH, Li LL, Wu GG, Xie YC, Zhang GX, Chen W, et al. Upregulation of CPE promotes cell proliferation and tumorigenicity in colorectal cancer. BMC Cancer. 2013;13:412.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Höring E, Harter PN, Seznec J, Schittenhelm J, Bühring HJ, Bhattacharyya S, et al. The “go or grow” potential of gliomas is linked to the neuropeptide processing enzyme carboxypeptidase E and mediated by metabolic stress. Acta Neuropathol. 2012;124:83–97.CrossRefPubMedGoogle Scholar
  29. 29.
    Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471–4.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  • Shiu-Feng Huang
    • 1
    • 2
  • Hong-Dar Isaac Wu
    • 3
  • Ya-Ting Chen
    • 1
  • Saravana R. K. Murthy
    • 4
  • Yu-Ting Chiu
    • 1
  • Yu Chang
    • 1
  • Il-Chi Chang
    • 1
  • Xuyu Yang
    • 4
  • Y. Peng Loh
    • 4
  1. 1.Institute of Molecular and Genomic MedicineNational Health Research InstitutesZhunaTaiwan
  2. 2.Department of Anatomical PathologyChung-Shan Medical University HospitalTaichungTaiwan
  3. 3.Department of Applied Mathematics and Institute of StatisticsNational Chung-Hsing UniversityTaichungTaiwan
  4. 4.Section on Cellular Neurobiology, Program on Developmental Neuroscience, Eunice Kennedy Shriver National Institute of Child Health and Human DevelopmentNational Institutes of HealthBethesdaUSA

Personalised recommendations